> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tirzepatide initiators stayed on treatment longer than semaglutide initiators
- URL: https://www.coios.me/tirzepatide-initiators-stayed-on-treatment-longer-than/
- Published: 2026-10-03T13:05:59.000Z
- Updated: 2026-10-03T17:39:00.000Z
- Description: In propensity-matched US claims data on adults with type 2 diabetes, 12-month adherence was 60% for tirzepatide initiators against 45% for semaglutide initiators among GLP-1-naive patients, with persistence of 62% against 47%.
- Author: Daniel Ryan
- Tags: Behavioural science, Adherence and persistence, Obesity, diabetes and GLP-1, United States, #peer-reviewed, #refines, #item, #source-2026-10

A retrospective cohort using the Healthcare Integrated Research Database matched adults with type 2 diabetes initiating tirzepatide or semaglutide between May 2022 and May 2023, stratified by prior GLP-1 receptor agonist exposure. Over 12 months, tirzepatide initiators had higher adherence (naive 60% vs 45%) and persistence (62% vs 47%), and a larger share reached the most stringent targets, including weight loss of at least 15% (23% vs 10% in naive patients). Pharmacy cost per patient reaching those targets was lower for tirzepatide at the stringent endpoints.

*Why it is interesting: Adherence and persistence for two incretin drugs compared in routine claims data, as observed continuation rather than trial exposure.*

Source

[Journal of Managed Care & Specialty Pharmacy, 1 October 2026](https://doi.org/10.18553/jmcp.2026.32.10.1173?ref=coios.me)

DOI

10.18553/jmcp.2026.32.10.1173

Type

Peer-reviewed article

Design

Retrospective propensity-matched claims and laboratory cohort, 10,702 GLP-1-naive and 5,577 non-naive pairs, initiation May 2022-May 2023, 12 months' follow-up

Verdict

Refines prior evidence

Driver

[Adherence and persistence](https://www.coios.me/d-adherence/)

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)